Controls severe nausea and vomiting. ANDA 216598, held by Amneal. Prochlorperazine Maleate.
As of Nov 16, 2026, ANDA 216598 (Prochlorperazine Maleate), held by Amneal, was first approved by FDA on Apr 17, 2023, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine maleate tablets are effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2023 | Original application | Approved | None posted |
| Prochlorperazine MaleateEQ 5MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Prochlorperazine MaleateEQ 10MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Jan 22, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 17, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters